Registry update — unassessed
Does Insulin Sensitivity Impact the Potential of Metformin to Slow Aging
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
RCTN=148Notable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 2, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The results do not establish whether metformin slows aging; the study measured surrogate biomarkers and mitochondrial changes over 12 weeks, not clinical aging outcomes or lifespan extension. The study does not determine whether observed changes in insulin sensitivity or mitochondrial function persist beyond the 12-week intervention period or translate to health benefits. The stratification by baseline insulin sensitivity may have created selection bias that limits generalizability to unselected aging populations.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 148
- Duration
- 3 months
- Population
- 148 subjects recruited from two sites (Oklahoma Medical Research Foundation and University of Wisconsin-Madison), free of type 2 diabetes, stratified to insulin sensitive or insulin resistant groups
- Primary outcome
- Insulin sensitivity
- Effect size
- —
- Significance
- Not reported
- Journal
- Oklahoma Medical Research Foundation
- Published
- Jul 2, 2026
Sources
Primary source
- Oklahoma Medical Research Foundation ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Aging is the number one risk factor for the majority of chronic diseases. There are no pharmaceutical treatments to slow aging and prolong healthspan. The anti-diabetic drug metformin is considered a likely pharmaceutical candidate to slow aging.
The investigators will use a dual-site, 12- week drug intervention trial performed in a double-blind, placebo-controlled manner on 148 subjects recruited from two separate sites (Oklahoma Medical Research Foundation (OMRF) and University of Wisconsin-Madison (UWM)).
After consent and initial subject screening for chronic disease, subjects will be stratified to insulin sensitive (IS) or insulin resistant (IR) groups. Over a 12- week intervention, half of each group will take metformin and half will take a placebo.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.